Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication.

BACKGROUND

Chronic myeloid leukemia (CML), is the first malignancy that related to the chromosomal abnormality and include 15-20% of all adulthood leukemia.

AIMS: This study aimed to compare the hematologic, breakpoint cluster region-abelson (BCR-ABL) and liver function enzymes changes during treatment period of Imatinib.

SETTINGS AND

DESIGN

A noncurrent clinical trial study.

MATERIALS AND

METHODS

New incident CML patients received Iranian made or Indian-made Imatinib after baseline measurement. Hematologic, BCR-ABL, electrolytes and liver function enzymes measured again after 24 weeks.

STATISTICAL ANALYSIS USED: Paired t-test and independent t-test was used to assess the effect of treatment in within and between groups, respectively.

RESULTS

Imatinib has a decreasing impact on white blood cells and placates. While an increasing effect on hemoglobin concentration. Iranian made and Indian-made Imatinib has a same effect on improvement of hematologic, BCR-ABL, electrolytes in CML patients. However, the liver changes of Imatinib were not clinically significant.

CONCLUSION

The Iranian-made Imatinib can be used as a replacement for Indian made ones without any statistical and clinical significant difference on Improvement of CML patients.